Vermillion holds off delisting with $20.5m from share sales:
This article was originally published in Clinica
Executive Summary
Diagnostics specialist Vermillion (formerly Ciphergen Biosystems) has received a timely financial boost - a windfall of $20.5m - from a private placement of approximately 24.4 million shares of common stock. The placement, made with a group of existing and new investors, will be used for general working capital and will be welcome relief to the Fremont, California-based firm, which was issued with a non-compliance letter from Nasdaq indicating a stockholders' equity below $2.5m; a market value of listed securities below $35m; or a net income of $500,000 for the previous fiscal year. Vermillion has until September 14 to regain compliance.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.